3 results
Approved WMOCompleted
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
Approved WMOWill not start
Primary: Safety and tolerability. Secondary: Effectiveness, quality of life, healthcare resource utilisation, work productivity.
Approved WMOCompleted
To determine if an on demand dosing of 50 or 150 mg of GSK557296 demonstratessuperior efficacy with respect to duration of IELT during an 8 week study periodcompared to placebo in men with premature ejaculation.To assess safety and tolerability of…